ELIQUIS/Bristol-Myers Squibb, Pfizer
Crystalline form N-1
Blood & blood forming organs
EU DMF readiness
US DMF readiness
Apixaban is a phenylpiperidine derivative, acts as antithrombotic or anticoagulant agent.
It is indicated to reduce the risk of stroke, systemic embolism in patients with non-valvular atrial fibrillation and for the prophylaxis of deep vein thrombosis (DVT), which may lead to pulmonary embolism (PE), in patients who have undergone hip or knee replacement surgery, treatment and prevention of the recurrence of venous thromboembolism (deep vein thrombosis and pulmonary thromboembolism).
It is formulated as tablets and film-coated tablets for oral route of administration.
Mechanism of action:
Apixaban is an anticoagulant direct factor Xa inhibitor. It is a reversible direct and selective inhibitor of factor Xa, which inhibits free and clot-bound factor Xa and prothrombinase activity, leading to indirect inhibition of platelet aggregation induced by thrombin which is responsible for activating fibrinogen and allowing clot formation. Apixaban plays an important role in inhibiting blood coagulation and preventing thrombosis.
The above product is presented solely for informational purposes and does not constitute an offer in any sense. Products with PIPELINE & EARLY DEVELOPMENT STATUS under patent (SPC) protection in Poland and/or other countries are not offered until expiration of the corresponding IP right.